Does Medicaid cover Wegovy or Zepbound in your state?

Why does Medicaid coverage depend on your state?

Federal law lets each state leave weight-loss drugs out of Medicaid, so covering Wegovy or Zepbound for weight alone is that state’s choice.^1,2

Medicaid is public health coverage for people with low incomes, run by each state within federal rules. The Medicaid drug law lists “agents when used for anorexia, weight loss, or weight gain” among the drugs a state may exclude.¹

Other uses aren’t optional. KFF, a health-policy research group, says coverage is required for GLP‑1s approved for diabetes.² It is also required for Wegovy’s heart use since March 2024 and Zepbound’s sleep apnea use since December 2024.²

Children are treated differently. KFF says coverage is also required when it is judged medically necessary for a child under Medicaid’s child health benefit (EPSDT, for people under 21).²

So Ozempic or Mounjaro for type 2 diabetes can be covered in every state, while weight-loss-only use depends on where you live.² Which uses insurers cover, and why, is in which uses of GLP‑1s insurance covers.

Which states cover Wegovy or Zepbound for weight loss?

Ten state Medicaid programs cover GLP‑1s for weight loss alone as of October 14, 2026, down from 13 in KFF’s January 2026 count.^{2,5,6,7,9,10,28,11,12,14,15,16}

Utah, Massachusetts and Rhode Island ended weight-loss coverage after KFF’s count.^17,18,19 Indiana has said it will start, but hadn’t published a date when we checked.²⁷

No state matches. Check the spelling, or clear the box.

“Weight loss alone” means a GLP‑1 prescribed for obesity or overweight, not for diabetes, heart, sleep apnea or liver uses. “Yes” rows rest on each state’s own notice, drug list or approval form, or a state Medicaid health plan’s policy. “No” rows rest on KFF’s January 2026 state survey; we found no later change. In every state, KFF says Medicaid must still cover these drugs for a child or young adult under 21 when judged medically necessary. Checked Oct 14, 2026.²

Mississippi’s Medicaid website refused our connection on October 14, 2026. Its row rests on KFF’s January 2026 map and an October 2025 KFF Health News report.^2,10

What do the 10 covering states ask for?

Every covering state needs your prescriber to send proof first, usually your BMI and a diet and activity plan; some set stricter limits.^5,6,15,16

This approval step is called prior authorization: the plan must agree before the pharmacy fills the prescription. BMI (body mass index) compares weight with height. Here is what each state’s documents say:

• Delaware: one Medicaid plan’s policy asks for a BMI over 30, or over 27, and in both cases at least one weight-related condition, such as high blood pressure or type 2 diabetes.⁵ The plan says the Delaware Medicaid State Plan requires the condition.⁵
• Kansas: BMI 30 or more, or 27 or more with a weight-related condition, plus a diet, activity and behavior plan.⁶
• Michigan: since January 1, 2026, only people classed as having severe (“morbid”) obesity, such as an adult BMI of 40 or more.^7,8 Other options must have failed, and the drug must be meant to avoid weight-loss surgery.⁷
• Minnesota: BMI 30 or more, or 27 or more with a weight-related condition, plus a diet and activity plan; renewal needs at least 5% weight loss.²⁸ Saxenda and Wegovy are preferred on the state drug list, and Zepbound is non-preferred.⁹
• Mississippi: doctors must document obesity levels and a treatment plan, then show weight loss every 6 months to renew.¹⁰
• Missouri: Zepbound and Foundayo for BMI 30 or more, or 27 or more with a weight-related condition.¹¹ Wegovy isn’t covered for weight loss there, only for heart risk or MASH, a liver disease with fat, inflammation and scarring.¹¹
• North Carolina: Wegovy is preferred. Zepbound or Saxenda need a failed trial of Wegovy, or a documented reason it can’t be used.^12,13
• Tennessee: Wegovy and Zepbound are preferred, both with prior authorization and quantity limits (a cap on how much is covered each month).¹⁴
• Virginia: BMI over 40, or over 37 with high blood fats, high blood pressure or type 2 diabetes.¹⁵ You must first have tried a weight-loss drug that isn’t a GLP‑1, unless you can’t tolerate any of them.¹⁵
• Wisconsin: BMI 30 or more, or 27 to under 30 with at least 2 risk factors such as high blood pressure or sleep apnea.¹⁶

“Preferred” drugs are the ones a state steers prescriptions to first. A non-preferred drug usually needs a failed trial of a preferred one, as North Carolina’s rule shows.¹² How prior authorization works step by step is in prior authorization for GLP‑1s.

Which states changed their rules in 2025 and 2026?

Seven states ended weight-loss coverage between January and October 2026 and Michigan narrowed it, while North Carolina dropped coverage in 2025 and then restored it.^{2,7,12,17,18,19,21,22,23,24}

1. Oct 1, 2026Rhode Island ended coverage of GLP‑1s for obesity or weight management, under the state’s budget for fiscal year 2027.^19,20
2. Jul 30, 2026Indiana’s governor directed its Medicaid agency to join the BALANCE Model to cover GLP‑1s for obesity.²⁷
3. Jul 3, 2026Massachusetts stopped covering anti-obesity drugs, including Wegovy and Zepbound, when used only for obesity or overweight.¹⁷
4. Jun 30, 2026Utah’s weight-loss coverage, a legislative pilot, ended. From June 1, its form allowed only renewals for people already approved.¹⁸
5. Jan 1, 2026California, New Hampshire, Pennsylvania (adults 21 and over) and South Carolina ended weight-loss coverage. Michigan narrowed its criteria.^{7,21,22,23,24}
6. Dec 12, 2025North Carolina restored coverage under the governor’s directive, with the criteria it used before.¹²
7. Oct 2025North Carolina dropped coverage during a state budget stalemate. KFF counted 16 covering states that month.²

Cost is the reason states give. South Carolina’s Medicaid agency said the drugs cost $2.3 million in state money and $5.5 million in federal money in its last fiscal year.²⁴ KFF says these four states’ cuts likely reflect state budget problems and the drugs’ significant costs.²

What does Medicaid still cover when weight loss isn’t covered?

States that dropped weight-loss coverage must still cover GLP‑1s for type 2 diabetes, and the California, Massachusetts and New Hampshire notices also keep heart, sleep apnea or liver uses.^2,17,21,22

• Massachusetts still covers these drugs for heart risk, sleep apnea and MASH.¹⁷ Wegovy became the only preferred drug for those uses.¹⁷
• California considers Zepbound requests only for sleep apnea, and since April 1, 2026 Wegovy for MASH needs no prior authorization.²¹
• New Hampshire kept coverage for diabetes, heart events, severe sleep apnea and MASH.²²
• Under 21: California, Massachusetts and Pennsylvania still review weight-loss requests for children and young adults under the EPSDT benefit.^17,21,23

How the heart and liver uses are covered is in Wegovy for heart protection and fatty liver. The sleep apnea use is in Zepbound for sleep apnea. If your state doesn’t cover weight-loss use, the makers’ own prices are in GLP‑1 costs without insurance.

What is the BALANCE Model, and which states have joined?

BALANCE is a voluntary federal program in which CMS (the Centers for Medicare & Medicaid Services, the federal agency that oversees Medicaid) negotiates GLP‑1 prices for state Medicaid programs; CMS’s model page names no participating state yet.²⁵

• Timing: state Medicaid programs can join from May 2026 through January 1, 2027.²⁵ KFF reported that applications were due July 31, 2026.²⁶
• Which drugs: eligible drugs must have reduced body weight by at least 9.5% on average in a randomized trial.²⁵
• Price: the Medicaid price is confidential, KFF says.²⁶ Indiana’s announcement put the cost at $245 a month per person, of which the state pays $85.16.²⁷
• No guarantee: CMS says the model won’t guarantee coverage for any person, and prior authorization rules apply.²⁵

Indiana is the only state we found that has announced it will join. On July 30, 2026, its governor directed the state Medicaid agency to take part, with eligibility rules and timing not yet available.²⁷ CMS’s page, last modified September 29, 2026, lists no participating states.²⁵

How do you check what your state covers?

Ask your state Medicaid program or your Medicaid health plan whether GLP‑1s are covered for weight, which brand is preferred, and what approval needs.³

1. Find your state program. Medicaid.gov lists every state’s Medicaid program and contacts.³
2. Ask about the use. Is a GLP‑1 covered for weight alone, or only for diabetes, heart, sleep apnea or liver uses?
3. Ask which brand is preferred. States differ: North Carolina prefers Wegovy, while Missouri covers Zepbound and Foundayo for weight loss.^11,13
4. Ask what approval needs. Expect BMI limits, a diet and activity plan, and sometimes an earlier weight-loss drug.^6,15,16
5. Ask how renewal works. Mississippi, for example, asks doctors to show weight loss every 6 months.¹⁰

If a Medicaid plan turns down a request, you can appeal and then ask for a state fair hearing: see how appeals work. A hearing can’t add a use your state has chosen to exclude, because federal law lets states leave weight-loss drugs out.¹

Questions people ask

How we researched this

More on insurance

USUnited StatesHow does Medicare cover GLP‑1 medicines like Ozempic, Wegovy and Zepbound?USUnited StatesWas your Wegovy or Zepbound denied? How do insurance appeals work?USUnited StatesWhich uses of GLP‑1s does insurance cover: weight, diabetes, heart, sleep apnea, PCOS?